

Adding high-dose, targeted radiation to the usual treatment for locally-advanced, inoperable non-small cell lung cancer

NRG
ONCOLOGY

Advancing Research. Improving Lives.™



Visit the patient
webpage for this
study:



ABOUT THE TRIAL

NRG-LU008 is a clinical study for people with non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest and is not able to be treated by surgery. Typically, people with NSCLC are treated with radiation therapy and chemotherapy, followed by the immune therapy drug ‘durvalumab;’ however, only approximately 33 out of 100 patients who receive this treatment plan are free of cancer at 5 years. NRG-LU008 was design to test if adding a higher dose of radiation directly to your lung tumor using a technique called Stereotactic Body Radiation Therapy or SBRT to the usual treatment can help patients live longer and delay the time without your cancer getting worse.

ABOUT NRG ONCOLOGY

As one of the five research groups in the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN), NRG Oncology carries out clinical trials on sex-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization includes investigators, medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians. The NRG Oncology includes more than 1,300 research sites worldwide, primarily in the United States and Canada. NRG Oncology is a non-profit research organization, funded mainly through grants from the NCI. To contact NRG Oncology, call 267-519-6630 or email info@nrgoncology.org

Frequently Asked Questions

What is a clinical trial?

Clinical trials are research studies that look to find better ways to prevent, diagnose, or treat disease.

Who can join this study?

If you are over the age of 18 with locally-advanced non-small cell lung cancer that cannot be removed with surgery, you may be able to participate.

Am I required to be in this study?

No. Taking part in this study is voluntary. You are free to choose to participate or not to participate. If you choose to participate in this study, you are able to leave the study at any time. If you decide not to take part in this study, your doctor will discuss other treatment options with you.

What are the possible treatments?

If you decide to take part in this study, you will get either standard radiation plus chemotherapy followed by immune therapy for up to 12 months (the usual approach), or you will get SBRT to the main tumor and standard radiation to the central lymph nodes and chemotherapy followed by immune therapy for up to 12 months (the study approach). SBRT uses special equipment to position you and precisely send the radiation directly to your tumor, sparing the healthy tissues in the rest of your chest.

How long will I be in this study?

After you finish your radiation treatment, your doctor will continue to follow your condition and watch you for side effects. You will be asked to visit the clinic every 3 months for one year, then every 6 months during years 2 and 3 after treatment, then yearly for life.

Are there side effects?

There may be some. The most common side effects of lung radiation include swelling and redness, tanning, thickening, numbness, or peeling of the skin at the area of radiation, difficulty or pain when swallowing, hair loss in treatment area, shortness of breath, cough, tiredness, diarrhea, nausea, anemia, infection, bleeding, bruising, or rib pain. The most common side effects of the chemotherapy drugs used on this study include allergic reactions, infection, bruising, bleeding, anemia, sores in mouth, diarrhea, nausea, pain, muscle weakness, numbness, hair loss, loss of appetite, weight loss, tiredness, kidney damage, hearing loss, and confusion. The most common side effects of immune therapy includes a cough. Your doctor will review all potential side effects with you.

MORE INFORMATION

Visit the National Cancer Institute website at <https://www.cancer.gov> for more information about studies or general information about cancer.

You may also call: 1-(800)-4-CANCER (1-800-422-6237).